The stock of Guardant Health Inc (NASDAQ: GH) has increased by 5.46 when compared to last closing price of 42.10. Despite this, the company has experienced a 13.35% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-06-03 that PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The Shield MCD test is a methylation-based blood test for the multi-cancer screening of multiple cancer types including bladder, colorectal, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 4.
Is It Worth Investing in Guardant Health Inc (NASDAQ: GH) Right Now?
The 36-month beta value for GH is at 1.38. Analysts have varying views on the stock, with 15 analysts rating it as a “buy,” 7 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for GH is 117.62M, and currently, shorts hold a 7.76% of that float. The average trading volume for GH on June 03, 2025 was 2.21M shares.
GH’s Market Performance
GH’s stock has seen a 13.35% increase for the week, with a -5.23% drop in the past month and a 7.04% gain in the past quarter. The volatility ratio for the week is 3.39%, and the volatility levels for the past 30 days are at 3.50% for Guardant Health Inc The simple moving average for the last 20 days is 10.27% for GH stock, with a simple moving average of 25.41% for the last 200 days.
Analysts’ Opinion of GH
Many brokerage firms have already submitted their reports for GH stocks, with Mizuho repeating the rating for GH by listing it as a “Outperform.” The predicted price for GH in the upcoming period, according to Mizuho is $55 based on the research report published on April 10, 2025 of the current year 2025.
Barclays, on the other hand, stated in their research note that they expect to see GH reach a price target of $60. The rating they have provided for GH stocks is “Overweight” according to the report published on January 23rd, 2025.
Guggenheim gave a rating of “Buy” to GH, setting the target price at $36 in the report published on June 28th of the previous year.
GH Trading at 3.42% from the 50-Day Moving Average
After a stumble in the market that brought GH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.10% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at GH starting from Joyce Meghan V., who proposed sale 100 shares at the price of $41.66 back on Jun 02 ’25. After this action, Joyce Meghan V. now owns shares of Guardant Health Inc, valued at $4,166 using the latest closing price.
Tariq Musa, the Director of Guardant Health Inc, sale 116 shares at $40.04 during a trade that took place back on May 19 ’25, which means that Tariq Musa is holding 3,479 shares at $4,645 based on the most recent closing price.
Stock Fundamentals for GH
Current profitability levels for the company are sitting at:
- -0.59 for the present operating margin
- 0.61 for the gross margin
The net margin for Guardant Health Inc stands at -0.54. The total capital return value is set at -0.41. Equity return is now at value -4584.47, with -27.33 for asset returns.
Based on Guardant Health Inc (GH), the company’s capital structure generated 1.24 points at debt to capital in total, while cash flow to debt ratio is standing at -0.21. The debt to equity ratio resting at -5.21. The interest coverage ratio of the stock is -166.83.
Currently, EBITDA for the company is -390.12 million with net debt to EBITDA at -1.53. When we switch over and look at the enterprise to sales, we see a ratio of 7.91. The receivables turnover for the company is 6.71for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.11.
Conclusion
In conclusion, Guardant Health Inc (GH) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
